SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-044594
Filing Date
2024-04-16
Accepted
2024-04-16 07:15:11
Documents
13
Period of Report
2024-04-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20240415.htm   iXBRL 8-K 47553
2 EX-99.1 clsd-ex99_1.htm EX-99.1 18166
3 GRAPHIC img171462827_0.jpg GRAPHIC 100147
  Complete submission text file 0000950170-24-044594.txt   323384

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20240415.xsd EX-101.SCH 24861
16 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20240415_htm.xml XML 4717
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 24846102
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)